223 related articles for article (PubMed ID: 37246171)
21. The impact of ICAM-1, CCL2 and TGM2 gene polymorphisms on differentiation syndrome in acute promyelocytic leukemia.
Mohammadzadeh Z; Omidkhoda A; Chahardouli B; Hoseinzadeh G; Moghaddam KA; Mousavi SA; Rostami S
BMC Cancer; 2021 Jan; 21(1):46. PubMed ID: 33422029
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor-mediated tissue transglutaminase overexpression couples acquired tumor necrosis factor-related apoptosis-inducing ligand resistance and migration through c-FLIP and MMP-9 proteins in lung cancer cells.
Li Z; Xu X; Bai L; Chen W; Lin Y
J Biol Chem; 2011 Jun; 286(24):21164-72. PubMed ID: 21525012
[TBL] [Abstract][Full Text] [Related]
23. Hyperglycemia-induced transcriptional regulation of ROCK1 and TGM2 expression is involved in small artery remodeling in obese diabetic Göttingen Minipigs.
Ludvigsen TP; Olsen LH; Pedersen HD; Christoffersen BØ; Jensen LJ
Clin Sci (Lond); 2019 Dec; 133(24):2499-2516. PubMed ID: 31830262
[TBL] [Abstract][Full Text] [Related]
24. Transcriptional control of transglutaminase 2 expression in mouse apoptotic thymocytes.
Sándor K; Daniel B; Kiss B; Kovács F; Szondy Z
Biochim Biophys Acta; 2016 Aug; 1859(8):964-74. PubMed ID: 27262403
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA‑214 suppresses the viability, migration and invasion of human colorectal carcinoma cells via targeting transglutaminase 2.
Shan H; Zhou X; Chen C
Mol Med Rep; 2019 Aug; 20(2):1459-1467. PubMed ID: 31173203
[TBL] [Abstract][Full Text] [Related]
26. TGM2 is a novel marker for prognosis and therapeutic target in colorectal cancer.
Miyoshi N; Ishii H; Mimori K; Tanaka F; Hitora T; Tei M; Sekimoto M; Doki Y; Mori M
Ann Surg Oncol; 2010 Apr; 17(4):967-72. PubMed ID: 20033322
[TBL] [Abstract][Full Text] [Related]
27. Tissue transglutaminase mediates the pro-malignant effects of oncostatin M receptor over-expression in cervical squamous cell carcinoma.
Caffarel MM; Chattopadhyay A; Araujo AM; Bauer J; Scarpini CG; Coleman N
J Pathol; 2013 Oct; 231(2):168-79. PubMed ID: 23765377
[TBL] [Abstract][Full Text] [Related]
28. Tissue transglutaminase is involved in mechanical load-induced osteogenic differentiation of human ligamentum flavum cells.
Chao YH; Huang SY; Yang RC; Sun JS
Connect Tissue Res; 2016 Jul; 57(4):307-18. PubMed ID: 27115725
[TBL] [Abstract][Full Text] [Related]
29. Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.
Gordon ER; Wright CA; James M; Cooper SJ
BMC Cancer; 2023 Jun; 23(1):524. PubMed ID: 37291514
[TBL] [Abstract][Full Text] [Related]
30. Tampering with cancer chemoresistance by targeting the TGM2-IL6-autophagy regulatory network.
Zhang H; McCarty N
Autophagy; 2017 Mar; 13(3):627-628. PubMed ID: 28056186
[TBL] [Abstract][Full Text] [Related]
31. AFF1 inhibits adipogenic differentiation via targeting TGM2 transcription.
Chen Y; Wang Y; Lin W; Sheng R; Wu Y; Xu R; Zhou C; Yuan Q
Cell Prolif; 2020 Jun; 53(6):e12831. PubMed ID: 32441391
[TBL] [Abstract][Full Text] [Related]
32. Targeting transglutaminase 2 partially restores extracellular matrix structure but not alveolar architecture in experimental bronchopulmonary dysplasia.
Mižíková I; Pfeffer T; Nardiello C; Surate Solaligue DE; Steenbock H; Tatsukawa H; Silva DM; Vadász I; Herold S; Pease RJ; Iismaa SE; Hitomi K; Seeger W; Brinckmann J; Morty RE
FEBS J; 2018 Aug; 285(16):3056-3076. PubMed ID: 29935061
[TBL] [Abstract][Full Text] [Related]
33. Cytosolic TGM2 promotes malignant progression in gastric cancer by suppressing the TRIM21-mediated ubiquitination/degradation of STAT1 in a GTP binding-dependent modality.
Zhang L; Li Q; Yang J; Xu P; Xuan Z; Xu J; Xu Z
Cancer Commun (Lond); 2023 Jan; 43(1):123-149. PubMed ID: 36353796
[TBL] [Abstract][Full Text] [Related]
34. Increased Osteoclastogenesis in Absence of TG2 Is Reversed by Transglutaminase Inhibition-Evidence for the Role for TG1 in Osteoclast Formation.
Ebrahimi Samani S; Kaartinen MT
Cells; 2023 Aug; 12(17):. PubMed ID: 37681871
[TBL] [Abstract][Full Text] [Related]
35. The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer.
Ai L; Kim WJ; Demircan B; Dyer LM; Bray KJ; Skehan RR; Massoll NA; Brown KD
Carcinogenesis; 2008 Mar; 29(3):510-8. PubMed ID: 18174247
[TBL] [Abstract][Full Text] [Related]
36. Transglutaminase 2 expression is increased as a function of malignancy grade and negatively regulates cell growth in meningioma.
Huang YC; Wei KC; Chang CN; Chen PY; Hsu PW; Chen CP; Lu CS; Wang HL; Gutmann DH; Yeh TH
PLoS One; 2014; 9(9):e108228. PubMed ID: 25247996
[TBL] [Abstract][Full Text] [Related]
37. Transglutaminase-2, RNA-binding proteins and mitochondrial proteins selectively traffic to MDCK cell-derived microvesicles following H-Ras-induced epithelial-mesenchymal transition.
Shafiq A; Suwakulsiri W; Rai A; Chen M; Greening DW; Zhu HJ; Xu R; Simpson RJ
Proteomics; 2021 Jul; 21(13-14):e2000221. PubMed ID: 33638284
[TBL] [Abstract][Full Text] [Related]
38. Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment.
Cao J; Huang W
PLoS One; 2016; 11(2):e0149388. PubMed ID: 26872016
[TBL] [Abstract][Full Text] [Related]
39. Up-regulation of TGM2 with ITGB1 and SDC4 is important in the development and metastasis of renal cell carcinoma.
Erdem M; Erdem S; Sanli O; Sak H; Kilicaslan I; Sahin F; Telci D
Urol Oncol; 2014 Jan; 32(1):25.e13-20. PubMed ID: 23499501
[TBL] [Abstract][Full Text] [Related]
40. A long non-coding RNA inside the type 2 transglutaminase gene tightly correlates with the expression of its transcriptional variants.
Minotti L; Baldassari F; Galasso M; Volinia S; Bergamini CM; Bianchi N
Amino Acids; 2018 Apr; 50(3-4):421-438. PubMed ID: 29313085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
